Press Release

Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes Maintenance of vision and anatomical improvements in study eye and fellow eye of patients previously treated First-in-class dendrimer nanomedicine that treats both eyes simultaneously with … Read more

Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present … Read more

New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha’s innovative nanomedicine programs REDWOOD CITY, Calif., Mar. 18, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, … Read more

Multiple subcutaneous doses safe and well-tolerated   >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes   >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients  Maintenance of BCVA and reduction of CST in these previously treated patients  Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections  REDWOOD … Read more

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the … Read more

Ashvattha receives additional financing up to $50 million with new lead investor Tribe Capital and existing investors led by Natural Capital Ashvattha’s at-home monthly subcutaneously-administered HDT (hydroxyl dendrimer therapeutic) for neovascular (wet) age-related macular degeneration (wet AMD) and diabetic macula edema (DME) demonstrated substantial reduction in treatment burden Interim Phase 2 trial results to be … Read more

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE model Ashvattha’s 18F-OP-801 PET imaging agent shows reduction in neuroinflammation following treatment with CSF1R dendranib Presentation by Stanford University collaborator nominated for Brain Imaging Council Young Investigator Award at … Read more

Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical model CSF1R dendranib (H74DS3M8) clinical candidate is orally bioavailable and designed to avoid safety concerns of other CSF1R tyrosine kinase inhibitors using Ashvattha’s proprietary hydroxyl dendrimer nanomedicine technology Reduction … Read more

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease Preliminary data expected in 1H 2024 REDWOOD CITY, Calif., February 22, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new … Read more

REDWOOD CITY, Calif., February 14, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences. Conference Details:  BIO CEO & Investor Conference … Read more